Treatment
Cell clinical trials
We’re tracking 5,545 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT07144280RecruitingPhase 3
Study of a new drug vs docetaxel for advanced lung cancer
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
Alabaster, AlabamaAges 18 years+ - NCT07115043RecruitingPhase 1/Phase 2
Study of AZD6750 for advanced solid tumors
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT06925464RecruitingPhase 1/Phase 2
Modified immune cells for T-cell lymphoma
This trial tests a new treatment where your own immune cells are modified to find and attack CD7-positive T-cell lymphoma cells. It is for people whose lymphoma has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 14–70 - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT07093411RecruitingEarly Phase 1
Targeted cell therapy for relapsed B-cell lymphoma
This trial tests a new type of cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is designed for patients whose lymphoma has not responded to or has returned after previous treatment, and who cannot or choose not to receive standard CAR-T therapy.
HefeiAges 18–75 - NCT07094685RecruitingPhase 2
Ivonescimab before surgery for head and neck cancer
This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
Ann Arbor, MichiganAges 18 years+ - NCT07058805RecruitingPhase 2
Radiation therapy after surgery for head and neck cancer
This trial tests whether giving radiation therapy in a specific way (compartmentalized) after surgery for head and neck cancer is safe and effective. It is for people with certain types of head and neck cancer that have been removed, and aims to improve outcomes while managing side effects.
BaselAges 18 years+ - NCT07061535RecruitingPhase 2
Sintilimab, tafolecimab and chemo for advanced small cell lung cancer
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
Changsha, HunanAges 18 years+ - NCT07022964RecruitingPhase 1/Phase 2
CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
BeijingAges 14–70 - NCT06088134Recruiting
Predicting survival after kidney cancer surgery with CT scans
This study uses a computer model to analyze your CT scans and predict how long you might stay cancer-free after surgery. It aims to help doctors personalize follow-up care for clear cell kidney cancer.
Chongqing, Chongqing MunicipalityAges Any age - NCT06997094RecruitingPhase 1
Decitabine plus standard therapy for HPV-negative head and neck cancer
This trial tests whether adding the drug decitabine to standard treatment (surgery and possibly radiation) can help people with a type of head and neck cancer not caused by HPV. You would receive decitabine before surgery, and then continue with standard care after.
Jacksonville, FloridaAges 18 years+ - NCT06992427RecruitingPhase 3
Gabapentin to prevent opioid use for mouth pain during cancer treatment
This trial tests if taking gabapentin during chemoradiation for head and neck cancer can reduce the need for strong painkillers like opioids. It may help manage mouth pain caused by treatment.
Gilbert, ArizonaAges 18 years+ - NCT05388695RecruitingPhase 1
Testing dual-target CAR T cells for B-cell blood cancers
This Phase 1 study tests CAR T cells designed to attack B-cell blood cancers using two targets (CD19 and CD20/CD22). It may help people whose cancer has come back or not responded to standard treatments, but it is mainly to check safety and early effectiveness.
Wuhan, HubeiAges 18–70 - NCT06859008RecruitingPhase 1
Zanubrutinib and sonrotoclax for B-cell lymphoma in diverse groups
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
Duarte, CaliforniaAges 18 years+ - NCT06863311RecruitingPhase 2
Trial of zanzalintinib with immunotherapy for advanced kidney cancer
This trial tests a new drug combination for people with advanced clear cell kidney cancer that has gotten worse after initial immunotherapy treatment. The goal is to see if adding zanzalintinib to another immunotherapy can help control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06045910RecruitingPhase 1/Phase 2
A study of ALETA-001 for certain B-cell blood cancers
This trial tests a new treatment called ALETA-001 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to previous treatments, including CAR T-cell therapy. It aims to see if ALETA-001 can help when standard options have not worked.
BirminghamAges 16 years+ - NCT06716658RecruitingPhase 2
New targeted drug for certain T/NK-cell lymphomas
This trial tests an oral JAK1 inhibitor called golidocitnib for people with T/NK-cell lymphoma that came back after treatment or didn't respond. The drug works by blocking a signal that helps cancer cells grow.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06639854Recruiting
CMV immunity test to guide antiviral prevention after transplant
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
Houston, TexasAges 18 years+ - NCT06606028Recruiting
Blood test for leftover cancer DNA after head and neck cancer treatment
This study uses a simple blood test to look for leftover cancer DNA after treatment for head and neck squamous cell carcinoma. The goal is to see if the test can find very small amounts of cancer early, which might help doctors make better decisions about follow-up care.
San Francisco, CaliforniaAges 18 years+ - NCT06588205Recruiting
Understanding MYC changes in aggressive B-cell lymphomas
This study looks at how changes in the MYC gene affect the outlook for people with certain fast-growing lymphomas, including diffuse large B-cell lymphoma and high-grade B-cell lymphoma. It aims to better understand the tumor environment and how these patients respond to standard chemotherapy.
AlessandriaAges 18–79 - NCT06550141RecruitingPhase 2
Preventing side effects of CAR-T therapy for large B-cell lymphoma
This trial tests whether a drug called emapalumab can reduce serious side effects from CAR-T cell therapy, a treatment for large B-cell lymphoma that has come back or not responded to earlier treatments. If you qualify, you would receive emapalumab alongside your CAR-T treatment to help make it safer.
Boston, MassachusettsAges 18 years+ - NCT06378190RecruitingPhase 1/Phase 2
New CAR-T cell therapy for relapsed B-cell lymphoma
This trial tests a new type of CAR-T cell therapy (a treatment that uses your own immune cells to fight cancer) for people with B-cell lymphomas that have come back or not responded to standard treatments. It aims to see if this new manufacturing method is safe and effective.
Barcelona, BarcelonaAges 18–80 - NCT06340737RecruitingPhase 1
CD22-targeting CAR T cells for relapsed B cell lymphoma
This trial tests whether giving modified immune cells (CAR T cells) that target CD22 on cancer cells can help people with certain B-cell lymphomas that have come back or not responded to at least two prior treatments. The goal is to see if this approach can shrink tumors or control the disease.
Palo Alto, CaliforniaAges 18 years+ - NCT06352242Recruiting
Study of immune activity after CAR-T therapy for lymphoma
This study looks at a biological process called trogocytosis (when immune cells swap pieces of their outer coating) to see if it can help predict how well CAR-T cell therapy works for people with a type of lymphoma called diffuse large B-cell lymphoma.
MontpellierAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,545 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.